Category: Insights

Pharmaceutical Formulary Management: Anticipating generic entry, identifying first generic entrants, and projecting drug price drops

Pharmaceutical formulary managers have a pressing need to manage their formulary budgets. Anticipating when drugs will face loss-of-exclusivity — when their key patents will expire — is an essential first-step…
The post Pharmaceutical Formulary Managem…


Measuring the knowledge translation and convergence in pharmaceutical innovation by funding-science-technology-innovation linkages analysis

This paper was originally published by Jian Du, Peixin Li, Qianying Guo, and Xiaoli Tang at Journal of Informetrics Volume 13, Issue 1, February 2019, Pages 132-148 under a a Creative Commons license.…
The post Measuring the knowledge translation and c…


Drug Spending in the US: Where the Money Actually Goes

Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
The post Drug Spending in the US: Where the Money Actually Goes appeared first on DrugPatentWatch – Make Better De…


Helping You Make Better Decisions: The DrugPatentWatch Design Philosophy

Anticipate the Future Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. We understand and work together with you to help you make better…
The post Helping You Make Better Decisions: The Dru…


How AI Is Already Changing Drug Development

The average time to market for a new drug is around 12 years, at a cost averaging $2.6 billion, according to 2014 research by Tufts University. And there’s no indication that…
The post How AI Is Already Changing Drug Development appeared first on DrugP…


Business Continuity and Resiliency Planning for Biomedical and Research Organizations

By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
The post Business Continuity and Resiliency…


Key Findings from GAO Report on Orphan Drug Approval Modernization

In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue.” It follows up on the FDA’s Orphan…
The post Key Findings from G…


Do NOT follow this link or you will be banned from the site!